Literature DB >> 23799515

Prevalence and predictors of elevated aspartate aminotransferase-to-platelet ratio index in Latin American perinatally HIV-infected children.

George K Siberry1, Rachel A Cohen, D Robert Harris, Maria Leticia Santos Cruz, Ricardo Oliveira, Mario F Peixoto, Maria Celia Cervi, Rohan Hazra, Jorge A Pinto.   

Abstract

BACKGROUND: Chronic liver disease has emerged as an important problem in adults with longstanding HIV infection, but data are lacking for children. We characterized elevated aspartate aminotransferase-to-platelet ratio index (APRI), a marker of possible liver fibrosis, in perinatally HIV-infected children.
METHODS: The National Institute of Child Health and Human Development International Site Development Initiative enrolled HIV-infected children (ages 0.1-20.1 years) from 5 Latin American countries in an observational cohort from 2002 to 2009. Twice yearly visits included medical history, physical examination and laboratory evaluations. The prevalence (95% confidence interval) of APRI > 1.5 was calculated, and associations with demographic, HIV-related and liver-related variables were investigated in bivariate analyses.
RESULTS: APRI was available for 1012 of 1032 children. APRI was >1.5 in 32 (3.2%, 95% confidence interval: 2.2%-4.4%) including 2 of 4 participants with hepatitis B virus infection. Factors significantly associated with APRI > 1.5 (P < 0.01 compared with APRI ≤ 1.5) included country, younger age, past or current hepatitis B virus, higher alanine aminotransferase, lower total cholesterol, higher log10 current viral load, lower current CD4 count, lower nadir CD4 count, use of hepatotoxic nonantiretroviral (ARV) medications and no prior ARV use. Rates of APRI > 1.5 varied significantly by current ARV regimen (P = 0.0002), from 8.0% for no ARV to 3.2% for non-protease inhibitor regimens to 1.5% for protease inhibitor-based regimens.
CONCLUSIONS: Elevated APRI occurred in approximately 3% of perinatally HIV-infected children. Protease inhibitor-based ARVs appeared protective whereas inadequate HIV control appeared to increase risk of elevated APRI. Additional investigations are needed to better assess potential subclinical, chronic liver disease in HIV-infected children.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23799515      PMCID: PMC3875831          DOI: 10.1097/INF.0b013e3182a01dfb

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  26 in total

1.  Assessment of liver fibrosis and cirrhosis by aspartate aminotransferase-to-platelet ratio index in children with biliary atresia.

Authors:  Sang Yong Kim; Jae Yeon Seok; Seok Joo Han; Hong Koh
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-08       Impact factor: 2.839

2.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.

Authors:  Richard K Sterling; Eduardo Lissen; Nathan Clumeck; Ricard Sola; Mendes Cassia Correa; Julio Montaner; Mark S Sulkowski; Francesca J Torriani; Doug T Dieterich; David L Thomas; Diethelm Messinger; Mark Nelson
Journal:  Hepatology       Date:  2006-06       Impact factor: 17.425

3.  HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease.

Authors:  David Nunes; Catherine Fleming; Gwynneth Offner; Michael O'Brien; Sheila Tumilty; Oren Fix; Timothy Heeren; Margaret Koziel; Camilla Graham; Donald E Craven; Sheri Stuver; C Robert Horsburgh
Journal:  J Acquir Immune Defic Syndr       Date:  2005-12-15       Impact factor: 3.731

4.  Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index.

Authors:  Thomas B Kelleher; Shruti H Mehta; Ramakrishnan Bhaskar; Mark Sulkowski; Jacquie Astemborski; David L Thomas; Richard E Moore; Nezam H Afdhal
Journal:  J Hepatol       Date:  2005-04-25       Impact factor: 25.083

5.  Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa.

Authors:  Raoul Moh; Christine Danel; Eugène Messou; Timothée Ouassa; Delphine Gabillard; Amani Anzian; Yao Abo; Roger Salamon; Emmanuel Bissagnene; Catherine Seyler; Serge Eholié; Xavier Anglaret
Journal:  AIDS       Date:  2007-11-30       Impact factor: 4.177

6.  Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy.

Authors:  Victor de Lédinghen; Brigitte Le Bail; Laurent Rebouissoux; Céline Fournier; Juliette Foucher; Véronique Miette; Laurent Castéra; Laurent Sandrin; Wassil Merrouche; Frédéric Lavrand; Thierry Lamireau
Journal:  J Pediatr Gastroenterol Nutr       Date:  2007-10       Impact factor: 2.839

7.  Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study.

Authors:  Helen Kovari; Bruno Ledergerber; Ulrich Peter; Markus Flepp; Josef Jost; Patrick Schmid; Alexandra Calmy; Nicolas J Mueller; Beat Muellhaupt; Rainer Weber
Journal:  Clin Infect Dis       Date:  2009-08-15       Impact factor: 9.079

8.  Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts.

Authors:  Erica E M Moodie; Nitika Pant Pai; Marina B Klein
Journal:  PLoS One       Date:  2009-02-18       Impact factor: 3.240

9.  Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality.

Authors:  Martin W G Brinkhof; Andrew Boulle; Ralf Weigel; Eugène Messou; Colin Mathers; Catherine Orrell; François Dabis; Margaret Pascoe; Matthias Egger
Journal:  PLoS Med       Date:  2009-04-28       Impact factor: 11.069

10.  Seroprevalence of hepatitis B and C viral co-infections among children infected with human immunodeficiency virus attending the paediatric HIV care and treatment center at Muhimbili National Hospital in Dar-es-Salaam, Tanzania.

Authors:  Safila P Telatela; Mecky I Matee; Emmanuel K Munubhi
Journal:  BMC Public Health       Date:  2007-11-22       Impact factor: 3.295

View more
  15 in total

1.  Prevalence and incidence of liver dysfunction and assessment of biomarkers of liver disease in HIV-infected Asian children.

Authors:  Linda Aurpibul; Torsak Bunupuradah; Sam Sophan; David Boettiger; Dewi K Wati; Lam V Nguyen; Vonthanak Saphonn; Rawiwan Hansudewechakul; Kulkanya Chokephaibulkit; Pagakrong Lumbiganon; Khanh H Truong; Viet C Do; Nagalingeswaran Kumarasamy; Nik K N Yusoff; Kamarul Razali; Nia Kurniati; Siew M Fong; Revathy Nallusamy; Annette H Sohn
Journal:  Pediatr Infect Dis J       Date:  2015-06       Impact factor: 2.129

2.  Validation of aspartate aminotransferase to platelet ratio for diagnosis of liver fibrosis and prediction of postoperative prognosis in infants with biliary atresia.

Authors:  Li-Yuan Yang; Jie Fu; Xiao-Fang Peng; Shu-Yin Pang; Kan-Kan Gao; Zheng-Rong Chen; Li-Juan He; Zhe Wen; Hui Wang; Le Li; Feng-Hua Wang; Jia-Kang Yu; Yi Xu; Si-Tang Gong; Hui-Min Xia; Hai-Ying Liu
Journal:  World J Gastroenterol       Date:  2015-05-21       Impact factor: 5.742

3.  [Noncirrhotic portal hypertension in a human immunodeficiency virus (HIV) infected adolescent].

Authors:  Aída de Fátima Thomé Barbosa Gouvêa; Daisy Maria Machado; Suênia Cordeiro de Vasconcelos Beltrão; Fabiana Bononi do Carmo; Regina Helena Guedes Motta Mattar; Regina Célia de Menezes Succi
Journal:  Rev Paul Pediatr       Date:  2015-03-27

4.  Prevalence of and progression to abnormal noninvasive markers of liver disease (aspartate aminotransferase-to-platelet ratio index and Fibrosis-4) among US HIV-infected youth.

Authors:  Bill G Kapogiannis; Erin Leister; George K Siberry; Russell B Van Dyke; Bret Rudy; Patricia Flynn; Paige L Williams
Journal:  AIDS       Date:  2016-03-27       Impact factor: 4.177

5.  Elevated aspartate aminotransferase-to-platelet ratio index in perinatally HIV-infected children in the United States.

Authors:  George K Siberry; Kunjal Patel; Jorge A Pinto; Ana Puga; Ayesha Mirza; Tracie L Miller; Russell B Van Dyke
Journal:  Pediatr Infect Dis J       Date:  2014-08       Impact factor: 2.129

6.  Getting to 90-90-90 in paediatric HIV: What is needed?

Authors:  Mary-Ann Davies; Jorge Pinto; Marlène Bras
Journal:  J Int AIDS Soc       Date:  2015-12-02       Impact factor: 5.396

7.  Prevalence and predictors of liver disease in HIV-infected children and adolescents.

Authors:  Maria Pokorska-Śpiewak; Aleksandra Stańska-Perka; Jolanta Popielska; Agnieszka Ołdakowska; Urszula Coupland; Konrad Zawadka; Małgorzata Szczepańska-Putz; Magdalena Marczyńska
Journal:  Sci Rep       Date:  2017-09-26       Impact factor: 4.379

8.  Role of the Aspartate Transaminase and Platelet Ratio Index in Assessing Hepatic Fibrosis and Liver Inflammation in Adolescent Patients with HBeAg-Positive Chronic Hepatitis B.

Authors:  Yu Zhijian; Li Hui; Yao Weiming; Lin Zhanzhou; Chen Zhong; Zheng Jinxin; Wang Hongyan; Deng Xiangbin; Yang Weizhi; Li Duoyun; Liu Xiaojun; Deng Qiwen
Journal:  Gastroenterol Res Pract       Date:  2015-07-05       Impact factor: 2.260

9.  The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected children.

Authors:  Rachel C Vreeman; Michael L Scanlon; Megan S McHenry; Winstone M Nyandiko
Journal:  J Int AIDS Soc       Date:  2015-12-02       Impact factor: 5.396

10.  Hepatic, Renal, Hematologic, and Inflammatory Markers in HIV-Infected Children on Long-term Suppressive Antiretroviral Therapy.

Authors:  Ann J Melvin; Meredith Warshaw; Alexandra Compagnucci; Yacine Saidi; Linda Harrison; Anna Turkova; Gareth Tudor-Williams
Journal:  J Pediatric Infect Dis Soc       Date:  2017-09-01       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.